Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Wednesday, September 15, 2021

Management of Diabetes Insipidus following Surgery for Pituitary and Suprasellar Tumours

xlomafota13 shared this article with you from Inoreader

Sultan Qaboos Univ Med J. 2021 Aug;21(3):354-364. doi: 10.18295/squmj.4.2021.010. Epub 2021 Aug 29.

ABSTRACT

Central diabetes insipidus (CDI) is a common complication after pituitary surgery. However, it is most frequently transient. It is defined by the excretion of an abnormally large volume of dilute urine with increasing serum osmolality. The reported incidence of CDI after pituitary surgery ranges from 0-90%. Large tumour size, gross total resection and intraoperative cerebrospinal fluid leak usually pose an increased risk of CDI as observed with craniopharyngioma and Rathke's cleft cysts. CDI can be associated with high morbidity and mortality if not promptly recognised and treated on time. It is also essential to rule out other causes of postoperative polyuria to avoid unnecessary pharmacotherapy and iatrogenic hyponatremia. Once the diagnosis of CDI is established, close monitoring is required to evaluate the response to treatment and to determine whether the CDI is transient or permanent. This review outlines the evaluation and management of patients with CDI following pituitary and suprasellar tumour surgery to help recognise the diagnosis, consider the differential diagnosis, initiate therapeutic interventions and guide monitoring and long-term management.

PMID:34522399 | PMC:PMC8407907 | DOI:10.18295/squmj.4.2021.010

View on the web

No comments:

Post a Comment